Patents by Inventor Ryu Nagata

Ryu Nagata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6576656
    Abstract: An oxindole of Formula 1 or a prodrug thereof, or a pharmaceutically acceptable salt thereof is useful for growth hormone releaser: wherein R1, R2, R3 and R4 are independently hydrogen, optionally substituted alkyl etc; R5 is optionally substituted aryl or optionally substituted heteroaryl; Z is —O— or —NH—; one of W1 and W2 is hydrogen, alkyl or —Y—CON(R10)R11; the other of W1 and W2 is n is 1, 2 or 3; m is 0, 1, 2 or 3; Y is single bond or C1-C3 alkylene; R6 and R7 are independently hydrogen, optionally substituted alkyl etc; R8 and R9 are independently hydrogen, optionally substituted alkyl etc; R10 and R11 are independently hydrogen, alkyl etc.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: June 10, 2003
    Assignee: Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Teruhisa Tokunaga, Takashi Umezome, W. Ewan Hume, Ryu Nagata, Kazuhiko Okazaki, Yasuyuki Ueki, Kazuo Kumagai
  • Patent number: 6495587
    Abstract: The present invention provides novel tricyclic indole-2-carboxylic acids of the following chemical formula, which have potent NMDA receptor antagonistic activity.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: December 17, 2002
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Nobuyuki Ae, Seiji Katayama, Hisakazu Kishimoto, Ryu Nagata
  • Publication number: 20020147204
    Abstract: A compound of the formula: 1
    Type: Application
    Filed: March 26, 2002
    Publication date: October 10, 2002
    Applicant: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
  • Patent number: 6384033
    Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: May 7, 2002
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
  • Patent number: 6194461
    Abstract: A compound represented by the figure (1) or a pharmaceutically acceptable salt thereof is useful as medicament for treating retinal degenerative disorders: wherein Ar is optionally substitued phenyl or optionally substituted heteroaryl;. n is 0, 1 or 2; W is —CH2NH— or —CH═N(O)—; R1, R2 and R3 are independently optionally substituted alkyl, carboxyl or alkoxycarbonyl; any two groups of R1, R2 and R3 may be taken together with the carbon atom to form optionally substituted cycloalkane; all of R1, R2 and R3 may be taken together with the adjusent carbon atom to form optionally substituted bicycloalkane or optionally substituted tricycloalkane; R4 and R5 are independently hydrogen atom or optionally substituted alkyl.
    Type: Grant
    Filed: March 15, 1999
    Date of Patent: February 27, 2001
    Assignee: Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Shuji Masumoto, Tatsuya Fujibayashi, Ryu Nagata
  • Patent number: 5719152
    Abstract: A tricyclic quinoxalinedione derivative represented by the formula 1: ##STR1## wherein X represents hydrogen, alkyl, halogen, cyano, trifluoromethyl, or nitro;R.sup.1 represents hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl;G represents --CONR.sup.2 -- or --NR.sup.2 CO--, wherein R.sup.2 represents hydrogen or alkyl;J represents an acidic group or a group which is convertible thereto in vivo;E represents an basic group or a group which is convertible thereto in vivo;Y represents a single bond, alkylene, alkenylene, substituted alkylene, or Y.sup.1 --Q--Y.sup.2, wherein Y.sup.1 represents a single bond or alkylene, Y.sup.2 represents alkylene, and Q represents a heteroatom selected from oxygen or sulfur;Z represents alkylene,or a pharmaceutically acceptable salt thereof, these compounds are selective antagonists of glycine binding site of the NMDA receptor.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: February 17, 1998
    Assignee: Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Ryu Nagata, Norihiko Tanno, Toru Kodo, Hiroshi Yamaguchi, Nobuyuki Ae
  • Patent number: 5616586
    Abstract: Tricyclic quinoxalinediones of the formula: ##STR1## wherein X is alkyl, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, etc.; R.sup.1 is H, etc.; R.sup.2 is H, alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkylalkyl, arylalkyl, substituted arylalkyl, aryl, or substituted aryl; W is H, CO.sub.2 R.sup.3, CO.sub.2 Y, CONR.sup.3 R.sup.4, CONR.sup.3 Y, CON(OR.sup.3)R.sup.4, COR.sup.3, CN, tetrazolyl, or substituted alkyl; R.sup.3 and R.sup.4 independently are H, alkyl, cycloalkyl, alkenyl, alkynyl, etc.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: April 1, 1997
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Ryu Nagata, Norihiko Tanno, Toru Kodo
  • Patent number: 5496843
    Abstract: A tricyclic indole-2-carboxylic acid derivative represented by the formula 1: ##STR1## wherein X represents alkyl, halogen or cyano;R.sup.1 represents hydrogen, or a protecting group of carboxyl group;W represents hydrogen, --CO.sub.2 R.sup.3i, --CONR.sup.3i R.sup.4i, --A--CO.sub.2 R.sup.3i or --A--CONR.sup.3i R.sup.4i, wherein --A-- represents alkylene and R.sup.3i and R.sup.4i independently represent hydrogen, alkyl, aryl or substituted aryl,or a pharmaceutically acceptable salt thereof, these compounds are selective antagonists of glycine binding site of the NMDA receptor.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: March 5, 1996
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Ryu Nagata, Norihiko Tanno, Nobuyuki Ae